(Q36594055)

English

A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer

scientific article published on 17 January 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 August 2017

A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer (English)

1 reference

Europe PubMed Central

15 August 2017

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

author name string

A Atmaca

1

1 reference

Europe PubMed Central

15 August 2017

S-E Al-Batran

2

1 reference

Europe PubMed Central

15 August 2017

D Werner

3

1 reference

Europe PubMed Central

15 August 2017

C Pauligk

4

1 reference

Europe PubMed Central

15 August 2017

T Güner

5

1 reference

Europe PubMed Central

15 August 2017

A Koepke

6

1 reference

Europe PubMed Central

15 August 2017

H Bernhard

7

1 reference

Europe PubMed Central

15 August 2017

T Wenzel

8

1 reference

Europe PubMed Central

15 August 2017

A-G Banat

9

1 reference

Europe PubMed Central

15 August 2017

P Brueck

10

1 reference

Europe PubMed Central

15 August 2017

K Caca

11

1 reference

Europe PubMed Central

15 August 2017

N Prasnikar

12

1 reference

Europe PubMed Central

15 August 2017

F Kullmann

13

1 reference

Europe PubMed Central

15 August 2017

H Günther Derigs

14

1 reference

Europe PubMed Central

15 August 2017

M Koenigsmann

15

1 reference

Europe PubMed Central

15 August 2017

G Dingeldein

16

1 reference

Europe PubMed Central

15 August 2017

T Neuhaus

17

1 reference

Europe PubMed Central

15 August 2017

E Jäger

18

1 reference

Europe PubMed Central

15 August 2017

language of work or name

0 references

publication date

17 January 2013

1 reference

Europe PubMed Central

15 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

15 August 2017

108

1 reference

Europe PubMed Central

15 August 2017

2

1 reference

Europe PubMed Central

15 August 2017

265-270

1 reference

Europe PubMed Central

15 August 2017

https://scigraph.springernature.com/pub.10.1038/bjc.2012.555

0 references

The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566804

9 September 2017

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566804

9 September 2017

Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566804

9 September 2017

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566804

9 September 2017

Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566804

9 September 2017

Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566804

9 September 2017

Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566804

9 September 2017

Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566804

9 September 2017

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566804

9 September 2017

Gemcitabine and oxaliplatin: a safe and active regimen in poor prognosis advanced non-small cell lung cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566804

9 September 2017

Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566804

9 September 2017

Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566804

9 September 2017

A dose escalation study of docetaxel and oxaliplatin combination in patients with metastatic breast and non-small cell lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566804

30 September 2017

Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566804

30 September 2017

Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.555

21 January 2018

Two-weekly gemcitabine fixed dose rate and oxaliplatin combination chemotherapy for advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.555

21 January 2018

Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experience.

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.555

21 January 2018

Oxaliplatin plus vinorelbine in advanced non-small-cell lung cancer: final results of a multicenter phase II study

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.555

21 January 2018

Docetaxel and oxaliplatin as first-line therapy for advanced non-small cell lung cancer: a phase II trial.

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.555

21 January 2018

Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC).

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.555

21 January 2018

The ALPI Trial: the Italian/European experience with adjuvant chemotherapy in resectable non-small lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.555

21 January 2018

A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.555

21 January 2018

[A randomized study of gemcitabine plus oxaliplatin versus gemcitabine plus cisplatin as the 1st line chemotherapy for advanced non-small cell lung cancer in elderly patients].

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566804

20 September 2018

A randomized trial comparing oxaliplatin plus vinorelbine versus cisplatin plus vinorelbine for the treatment of patients with advanced non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566804

20 September 2018

[Efficacy of NO regimen and NP regimen on advanced non-small cell lung cancer: a prospective randomized trial]

1 reference

https://pubmed.ncbi.nlm.nih.gov/23329236

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase III randomized trial of gemcitabine-oxaliplatin versus carboplatin-paclitaxel as first-line therapy in patients with advanced non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23329236

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BJC.2012.555

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

15 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36594055&oldid=1640106568"